The Proof-of-Concept A.L.I.C.E. or "Actuators based on Light sensitive CompositE" aims at the development of innovative materials through 3D/4D printing processes and uses them as actuators in the fields of photovoltaics, concentrated solar power, thermodynamic solar, and other applications such as optical deflectors, optical microvalves, and optical switches.
Technologies
In this section it is possible to view, also through targeted research, the technologies inserted in the PROMO-TT Database. For further information on the technologies and to contact the CNR Research Teams who developed them, it is necessary to contact the Project Manager (see the references at the bottom of each record card).
Displaying results 1 - 5 of 5
The proposal concerns the development of the G.A.T.CD4 (Gliadin-activated CD4+ T cells) method which allows, in peripheral blood, the identification of CD4+ T lymphocytes reactive to toxic peptides of gliadin, the main gluten protein of cereals.
The development of new materials with near-infrared emission (NIR, 700 – 1000 nm) represent an important target in the technological progress of innovative active components for OLED devices (including flexible ones), surveillance systems, autonomous driving, night vision sensors, fiber optic telecommunications and medical systems. In all these fields it still lacks a commercial NIR-OLED technology.
The technology refers to a system for the safety and control of the mobility of vehicles, pedestrians, and mass transport users, in conventional and advanced contexts and is suitable for use as an infrastructure for the production/sharing of information and data, aimed at monitoring and intervention in critical areas by offering specific functions concerning the detection of potentially dangerous situations or the optimization of resources.
Our treatment demonstrated the ability to kill metastatic human melanoma cells, for which there are very few effective therapeutic approaches. Use of a specific Essential Oil (EO) to inhibit the replication of human metastatic melanoma cells. This EO can be used both for direct application to the skin, and administered by mouth to reach both primary and metastatic melanomas.